The ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma were developed to provide evidence-based recommendations for the diagnosis, treatment, and follow-up of this common gynecological cancer. The guidelines were updated in 2020 to reflect the latest scientific evidence and address new topics. Endometrial carcinoma is the most common gynecological cancer in Europe, with a 5-year prevalence of 34.7%. The guidelines aim to improve the quality of care for women with endometrial carcinoma across Europe and globally. The guidelines emphasize the importance of a multidisciplinary approach, including gynecological oncologists, surgeons, pathologists, and other specialists. They cover various aspects of endometrial carcinoma, including the identification and surveillance of women with pathogenic germline variants in Lynch syndrome-associated genes, molecular markers for diagnosis and treatment decisions, and the definition of prognostic risk groups. The guidelines also address the management of early-stage disease, surgical procedures, lymph node staging, fertility preservation, and adjuvant treatment. Key recommendations include the use of molecular classification for endometrial carcinoma, the importance of sentinel lymph node biopsy for lymph node staging, and the consideration of fertility-sparing treatments for patients with low-grade endometrioid carcinoma. The guidelines also provide recommendations for the management of medically unfit patients and the use of radiotherapy and systemic treatment in cases where surgery is not possible. The guidelines emphasize the importance of individualized treatment plans based on the patient's specific circumstances, including the risk of recurrence, the presence of genetic mutations, and the patient's desire to preserve fertility. They also highlight the need for close follow-up and surveillance for patients with Lynch syndrome and those at high risk of recurrence. Overall, the guidelines aim to provide a comprehensive and evidence-based approach to the management of endometrial carcinoma, ensuring that patients receive the best possible care.The ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma were developed to provide evidence-based recommendations for the diagnosis, treatment, and follow-up of this common gynecological cancer. The guidelines were updated in 2020 to reflect the latest scientific evidence and address new topics. Endometrial carcinoma is the most common gynecological cancer in Europe, with a 5-year prevalence of 34.7%. The guidelines aim to improve the quality of care for women with endometrial carcinoma across Europe and globally. The guidelines emphasize the importance of a multidisciplinary approach, including gynecological oncologists, surgeons, pathologists, and other specialists. They cover various aspects of endometrial carcinoma, including the identification and surveillance of women with pathogenic germline variants in Lynch syndrome-associated genes, molecular markers for diagnosis and treatment decisions, and the definition of prognostic risk groups. The guidelines also address the management of early-stage disease, surgical procedures, lymph node staging, fertility preservation, and adjuvant treatment. Key recommendations include the use of molecular classification for endometrial carcinoma, the importance of sentinel lymph node biopsy for lymph node staging, and the consideration of fertility-sparing treatments for patients with low-grade endometrioid carcinoma. The guidelines also provide recommendations for the management of medically unfit patients and the use of radiotherapy and systemic treatment in cases where surgery is not possible. The guidelines emphasize the importance of individualized treatment plans based on the patient's specific circumstances, including the risk of recurrence, the presence of genetic mutations, and the patient's desire to preserve fertility. They also highlight the need for close follow-up and surveillance for patients with Lynch syndrome and those at high risk of recurrence. Overall, the guidelines aim to provide a comprehensive and evidence-based approach to the management of endometrial carcinoma, ensuring that patients receive the best possible care.